A real-world pharmacovigilance study of blinatumomab based on the FDA adverse event reporting system
This pharmacovigilance study utilizing the FAERS database identified potential AE signals associated with blinatumomab, providing essential insights for its safe clinical use.
Authors
- Xia Song (ORCID: https://orcid.org/0000-0002-4219-7193)
- Wenhao Guo (ORCID: https://orcid.org/0000-0002-3261-1864)
- Yuping Wang (ORCID: https://orcid.org/0000-0002-6482-9710)
- Qianzhi Yang
- Minghao Chen
- Zheng Zhang (ORCID: https://orcid.org/0009-0006-9558-6535)
Institutions
- Lanzhou University Second Hospital (CN)
- First Affiliated Hospital of Jinan University (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1080/14740338.2025.2464070
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00